{
    "eid": "2-s2.0-85117200005",
    "title": "Heparin-induced thrombocytopenia in patients with COVID-19: A systematic review and meta-analysis",
    "cover-date": "2021-11-09",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Noppacharn Uaprasert",
        "Nuanrat Tangcheewinsirikul",
        "Ponlapat Rojnuckarin",
        "Rushad Patell",
        "Jeffrey I. Zwicker",
        "Thita Chiasakul"
    ],
    "citedby-count": 13,
    "ref-count": 47,
    "ref-list": [
        "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia",
        "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study",
        "Prevalence and impact of coagulation dysfunction in COVID-19 in China: A meta-analysis",
        "Systemic coagulopathy in hospitalized patients with coronavirus disease 2019: A systematic review and meta-analysis",
        "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy",
        "Incidence of venous thromboembolism in hospitalized patients with COVID-19",
        "Incidence of thrombotic complications in critically ill ICU patients with COVID-19",
        "Venous thromboembolism in critically Ill patients with COVID-19: Results of a screening study for deep vein thrombosis",
        "ISTH interim guidance on recognition and management of coagulopathy in COVID-19",
        "Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19",
        "Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019",
        "American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19",
        "High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients",
        "COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection",
        "Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: A pooled analysis",
        "Coagulopathy of hospitalised COVID-19: A pragmatic randomised controlled trial of therapeutic anticoagulation versus standard care as a rapid response to the COVID-19 pandemic (RAPID COVID COAG-RAPID Trial): A structured summary of a study protocol for a randomised controlled trial",
        "Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): A structured summary of a study protocol",
        "Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial",
        "Heparin-induced thrombocytopenia",
        "Heparin-induced thrombocytopenia in the critically ill patient",
        "Comparison of diagnostic performance of the heparin-induced thrombocytopenia expert probability and the 4Ts score in screening for heparin-induced thrombocytopenia",
        "Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement",
        "Assessing risk of bias in prevalence studies: Modification of an existing tool and evidence of interrater agreement",
        "Measuring inconsistency in meta-analyses",
        "Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome",
        "Heparin-induced thrombocytopenia in COVID-19",
        "The challenges of diagnosing heparin-induced thrombocytopenia in patients with COVID-19",
        "Heparin induced thrombocytopenia antibodies in Covid-19 [published online ahead of print 13 July]",
        "Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: Two case reports",
        "SARS-CoV-2 and pulmonary embolism: who stole the platelets?",
        "Heparin-induced thrombocytopenia in severe COVID-19",
        "Contrast between prevalence of HIT antibodies and confirmed HIT in hospitalized COVID-19 patients: A prospective study with clinical implications",
        "High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study",
        "Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis",
        "The rationale for the use of unfractionated heparin (UFH) in the treatment of thromboembolic events (TE) in patients infected with COVID-19",
        "Heparin-induced thrombocytopenia in patients with COVID-19",
        "Is COVID-19 an independent risk factor for heparin-induced thrombocytopenia?",
        "Autoimmune heparin-induced thrombocytopenia: A rare manifestation of COVID-19",
        "Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19",
        "COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies",
        "Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission",
        "Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis",
        "Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies",
        "Heparin-induced thrombocytopenia in intensive care patients",
        "COVID-19 induces a hyperactive phenotype in circulating platelets",
        "Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60002746",
            "affilname": "Harvard Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}